Skip to main content

Low prevalence of antibodies and other plasma factors binding to CC chemokines and IL-2 in HIV-positive patients

Buy Article:

$51.00 plus tax (Refund Policy)


Neutralizing cytokine antibodies are found in healthy and diseased individuals, including patients treated with recombinant cytokines. Identification of CCR-5 as co-receptor for HIV has focused interest on CC chemokines and their potential therapeutic use. Chemokine-binding components in plasma of HIV-infected patients were therefore assessed by radioimmunoassay and radioreceptor assay. IgG from 4/505 HIV patients and 9/2000 healthy controls (p>0.05) bound rMIP-1α and rMIP-1β, but not rRANTES. No other plasma factors bound the chemokines. The antibodies inhibited receptor binding of both chemokines. There was no association between presence of antibodies and disease stage or HIV progression rate. Three of 11 patients treated with rIL-2 developed IgG antibodies suppressing cellular binding and growth promotion of rIL-2. Hence, circulating factors, including antibodies MIP-1α/MIP-1β, are uncommon in healthy individuals and HIV patients, and are apparently without prognostic significance. In contrast to earlier reports, IL-2 antibodies were found only in HIV patients treated with rIL-2.

Keywords: Antibodies; CC chemokines; HIV infection; IL-2; cytokine therapy

Document Type: Original Article


Affiliations: 1: Institute for Inflammation Research, Rigshospitalet National University Hospital, Copenhagen, and 2: Department of Medicine and Infectious Diseases, Marselisborg Hospital, Århus, 3: Institute of Medical Microbiology and Immunology, Panum Institute, Copenhagen University, Copenhagen, and 4: Department of Infectious Diseases, Rigshospitalet National University Hospital, Copenhagen, Denmark

Publication date: February 1, 2000


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more